Supporting new treatment access

Have your say on new myeloma treatments. Your submission helps decide which treatments receive government funding.

Which Government committee makes treatment funding decisions?

In Australia, there are two government advisory committees that determine whether to recommend that a medicine or medical technology should be subsidised. These two committees are:

As part of their decision-making process, these committees not only consider how clinically and cost effective a new medicine or technology is, they also invite people with myeloma, as well as their carer/s and family, to have their say on how this medicine or technology would benefit them.

They do this through inviting consumer comments.

What should I include in a consumer comment submission?

The committee asks for you to be as specific as possible in your consumer comment submission. They want to know about:

  • your experience of living with myeloma or supporting someone with myeloma.
  • how important it is to have new treatments available when you need them
  • how living with myeloma affects you or your support network
  • your experiences with the drug if you have accessed it on clinical trial
  • how your current treatment impacts your life.

How to make a submission

PBAC

There are two myeloma related items on the agenda for the March 2027 meeting. They are: 

1. Daratumumab, bortezomib and dexamethasone (DVRd) for the treatment of people with myeloma who are newly diagnosed and deemed eligible for an autologous stem cell transplant. 
 
2. Teclistamab for people with myeloma who have had at least one prior line of therapy 

These applications are an important step forward in our mission to have access to newer therapies earlier in the treatment pathway. 

If you would like to support both items, you will need to make two separate submissions. See above for some information about what to include in your submission. 

You can make a submission one of three ways:

Online

Use the latest Consumer Comments Portal

Email

Email pbac@health.gov.au

Letter

Address a written letter to:

Professor Robyn Ward
Chair PBAC at PBAC Secretariat,
MDP 952, Pharmaceutical Evaluation Branch,
Department of Health and Aged Care
GPO Box 9848,
Canberra, ACT,
2601

MSAC

MSAC have previously recommended the use of the CAR T-cell therapy Carvykti for people with myeloma who have had four prior lines of therapy. They are now reviewing an application to allow access to Carvykti for people with myeloma who have had at least one prior line of therapy. 

To read more about CAR T-cell therapy CLICK HERE. 

You can tell MSAC why having access to Carvykti earlier in the treatment pathway is important to you. See above for some information about what to include in your submission. 

Please submit your comment using one of the methods outlined below:

Online

Online through MSAC Consultations

Email

Email commentsmsac@health.gov.au

Letter

Address a written letter to:

Professor Jonathan Craig,
MSAC Secretariat, MDP 960
GPO Box 9848,
ACT
2601

Telephone Support Line

Talk directly with our Specialist Myeloma Nurses who understand exactly what you’re going through.

Use our simple booking form below to schedule your personalised consultation at a time that works for you.

Get the expert guidance and emotional support you need, when you need it most.